Chairman of Morningside Pharmaceuticals Dr Nik Kotecha gives his views on the Brexit Trade Deal agreed at the end of 2020.
Dr Nik Kotecha OBE, said: “Uncertainty has dogged the UK’s business community and the wider economy since the referendum in 2016; so it’s great news that a deal has been agreed with the European Union just before the Christmas break.
“This deal delivers certainty and will enable companies to finally be able to make long term plans, as well as invest for the future, and what a bright future it could be. It also means that the UK will be able to continue to trade with minimal tariffs and disruption with the EU, which is by far our largest and closest trading partner. Saying this, the way we trade with the EU is changing and things will not be how they were, from the start of 2021.
“I am a great admirer of how UK businesses are able to adapt and innovate, as their operating environments evolve. As an independent sovereign nation there are likely to be many opportunities for businesses to grow into new markets, as the UK continues to sign trade deals around the world.
“Morningside was established as an 100% export-led business in the 1990s, supplying Aid to lower to middle income countries via international Aid Organisations. We have since become a leading manufacturer and supplier of generic medicines to the NHS, hospitals and pharmacies in the UK; so I have seen first-hand the opportunities which are out there, and the huge benefits on offer for UK Plc.
“On December 31st 2020 the Transition Period will end and there will still be some big changes, which UK businesses must prepare for now. But they can be confident that the New Year will bring a fresh start and most importantly of all – certainty – for the first time in a long while.”
This article was written by Medilink Midlands Patron, Morningside Pharmaceuticals.
